Co-administration of resveratrol with doxorubicin in young mice attenuates detrimental late-occurring cardiovascular changes

摘要

AimsDoxorubicin (DOX) is among the most effective chemotherapies used in paediatric cancer patients. However, the clinical utility of DOX is offset by its well-known cardiotoxicity, which often does not appear until later in life. Since hypertension significantly increases the risk of late-onset heart failure in childhood cancer survivors, we investigated whether juvenile DOX exposure impairs the ability to adapt to angiotensin II (Ang II)–induced hypertension later in life and tested a treatment that could prevent this.